Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA.

J Clin Oncol. 2012 Jun 10;30(17):2063-9. doi: 10.1200/JCO.2011.40.1315. Epub 2012 Apr 30.

2.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group.

J Clin Oncol. 2005 Sep 1;23(25):5892-9. Epub 2005 Jul 25.

PMID:
16043829
3.

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, Fukuoka M.

Lung Cancer. 2017 Feb;104:119-125. doi: 10.1016/j.lungcan.2016.11.022. Epub 2016 Nov 30.

4.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
5.

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR.

J Clin Oncol. 2011 Sep 10;29(26):3567-73. doi: 10.1200/JCO.2010.34.4929. Epub 2011 Aug 8. Erratum in: J Clin Oncol. 2011 Oct 10;29(29):3948. Camidge, Ross [corrected to Camidge, D Ross].

7.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
8.

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).

Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Int J Clin Oncol. 2018 Dec;23(6):1060-1069. doi: 10.1007/s10147-018-1318-z. Epub 2018 Jul 19.

9.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.

Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR.

J Thorac Oncol. 2016 Mar;11(3):420-5. doi: 10.1016/j.jtho.2015.11.003. Epub 2015 Dec 25.

10.

Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH.

Lung Cancer. 2014 May;84(2):196-202. doi: 10.1016/j.lungcan.2014.01.022. Epub 2014 Feb 3.

PMID:
24629638
11.

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM.

J Clin Oncol. 2009 Jan 10;27(2):264-70. doi: 10.1200/JCO.2008.17.4656. Epub 2008 Dec 1.

12.

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.

Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.

Asia Pac J Clin Oncol. 2012 Sep;8(3):232-43. doi: 10.1111/j.1743-7563.2012.01518.x. Epub 2012 Apr 23.

PMID:
22897752
13.

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C.

Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.

PMID:
21783417
14.

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.

J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17.

PMID:
26573867
15.

Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.

Xu JL, Jin B, Ren ZH, Lou YQ, Zhou ZR, Yang QZ, Han BH.

PLoS One. 2015 Jul 6;10(7):e0131278. doi: 10.1371/journal.pone.0131278. eCollection 2015. Review.

16.

Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.

Shen YC, Tseng GC, Tu CY, Chen WC, Liao WC, Chen WC, Li CH, Chen HJ, Hsia TC.

Lung Cancer. 2017 Aug;110:56-62. doi: 10.1016/j.lungcan.2017.06.007. Epub 2017 Jun 13.

PMID:
28676220
17.

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ.

J Clin Oncol. 2005 Sep 1;23(25):5900-9. Epub 2005 Jul 25.

PMID:
16043828
18.

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.

Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):317-24. doi: 10.1016/j.ijrobp.2015.02.005.

19.

Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.

Erdogan B, Kodaz H, Karabulut S, Cinkaya A, Tozkir H, Tanriverdi O, Cabuk D, Hacioglu MB, Turkmen E, Hacibekiroglu I, Uzunoglu S, Cicin I.

Bosn J Basic Med Sci. 2016 Nov 10;16(4):280-285. doi: 10.17305/bjbms.2016.1380.

20.

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T.

Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7. Epub 2013 Jun 17.

PMID:
23782814

Supplemental Content

Support Center